Cervarix two-dose HPV vaccine administration now approved for girls aged 9 to 14

SINGAPORE - Girls, aged 9 to 14, in Singapore can opt for a easier implementation schedule for human papillomavirus (HPV) vaccination. Singapore has approved a two-dose administration of cervical cancer vaccine Cervarix for girls aged 9 to 14, said GlaxoSmithKline in a press statement.

Two studies that assessed the effectiveness and safety of Cervarix found that two doses in 9 to 14 year old girls are comparable to three doses in 15 to 25 year old girls and women. In one study, the results were sustained for a total of four years.

The new two-dose schedule of Cervarix is available to girls aged 9 to 14 years as an alternative to the current three-dose schedule. Cervarix is indicated in females from 9 to 25 years of age for the prevention of persistent infection, premalignant cervical lesions and cervical cancer caused by Human Papillomavirus Types 16 & 18.

At present, the three-dose schedule remains the only licensed indication for girls and women aged 15 years and above.